RB Capital Management LLC bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,227 shares of the biopharmaceutical company’s stock, valued at approximately $364,000.
Other large investors also recently added to or reduced their stakes in the company. P.R. Herzig & Co. Inc. boosted its stake in Bristol-Myers Squibb by 13.5% in the third quarter. P.R. Herzig & Co. Inc. now owns 5,041 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 600 shares in the last quarter. National Pension Service raised its position in Bristol-Myers Squibb by 8.8% in the third quarter. National Pension Service now owns 1,018,161 shares of the biopharmaceutical company’s stock valued at $54,899,000 after buying an additional 81,955 shares during the last quarter. Private Trust Co. NA raised its position in Bristol-Myers Squibb by 16.2% in the third quarter. Private Trust Co. NA now owns 73,392 shares of the biopharmaceutical company’s stock valued at $3,957,000 after buying an additional 10,246 shares during the last quarter. Murphy Pohlad Asset Management LLC raised its position in Bristol-Myers Squibb by 5.5% in the third quarter. Murphy Pohlad Asset Management LLC now owns 5,268 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 275 shares during the last quarter. Finally, Community Bank N.A. raised its position in Bristol-Myers Squibb by 4.4% in the third quarter. Community Bank N.A. now owns 30,890 shares of the biopharmaceutical company’s stock valued at $1,666,000 after buying an additional 1,315 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co (NYSE:BMY) traded up 0.23% during midday trading on Thursday, reaching $53.32. The company had a trading volume of 2,127,643 shares. Bristol-Myers Squibb Co has a 52-week low of $46.01 and a 52-week high of $77.12. The company has a market cap of $89.19 billion, a PE ratio of 20.12 and a beta of 1.00. The company’s 50-day moving average is $55.44 and its 200 day moving average is $54.63. Bristol-Myers Squibb also was the recipient of unusually large options trading on Wednesday. Traders bought 3,241 call options on the company. This is an increase of 437% compared to the typical volume of 603 call options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 EPS for the quarter, missing the Zacks’ consensus estimate of $0.67 by $0.04. Bristol-Myers Squibb had a return on equity of 31.39% and a net margin of 22.94%. The company earned $5.24 billion during the quarter, compared to the consensus estimate of $5.14 billion. During the same period in the previous year, the business earned $0.38 earnings per share. Bristol-Myers Squibb’s revenue was up 22.3% on a year-over-year basis. On average, equities research analysts forecast that Bristol-Myers Squibb Co will post $2.80 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Friday, April 7th will be given a $0.39 dividend. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.93%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 58.87%.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/04/20/rb-capital-management-llc-buys-new-stake-in-bristol-myers-squibb-co-bmy-updated.html.
BMY has been the topic of a number of analyst reports. Jefferies Group LLC dropped their price objective on shares of Bristol-Myers Squibb to $60.00 in a research note on Friday, January 27th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Saturday, January 21st. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a research report on Tuesday, December 27th. Gabelli reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Thursday, February 9th. Finally, Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $59.49 price objective for the company. in a report on Tuesday, February 14th. Twelve research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $62.48.
In other news, Director Theodore R. Samuels II purchased 12,000 shares of the stock in a transaction on Monday, February 27th. The shares were acquired at an average price of $56.77 per share, for a total transaction of $681,240.00. Following the completion of the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $681,240. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Louis S. Schmukler sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $56.49, for a total value of $282,450.00. Following the sale, the insider now owns 21,483 shares in the company, valued at approximately $1,213,574.67. The disclosure for this sale can be found here. Insiders sold 190,501 shares of company stock worth $10,690,203 in the last quarter. 0.24% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.